Daniel M Halperin
Overview
Explore the profile of Daniel M Halperin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
645
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morse M, Crosby E, Halperin D, Uronis H, Hsu S, Hurwitz H, et al.
J Neuroendocrinol
. 2025 Feb;
:e13496.
PMID: 39933708
While performing a study of immune checkpoint blockade with the anti-PD-1 antibody pembrolizumab combined with the somatostatin analogue (SSA) lanreotide in patients with low- and intermediate-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs),...
2.
Bhamidipati D, Johnson J, Lin K, Pelicano H, Eng C, Huey R, et al.
Cancers (Basel)
. 2025 Jan;
17(2.
PMID: 39858090
Background: To extend the practicality of liquid biopsy beyond the historical HPV circulating tumor DNA (ctDNA) assays, we evaluated the clinical relevance of a novel next-generation sequencing HPV ctDNA assay...
3.
Serrano A, Rocha P, Lima C, Stewart A, Zhang B, Diao L, et al.
NPJ Precis Oncol
. 2024 Nov;
8(1):268.
PMID: 39558076
Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well...
4.
Fields B, Ayabe R, Seo Y, Maxwell J, Halperin D
Curr Oncol Rep
. 2024 Oct;
26(11):1530-1542.
PMID: 39466478
Purpose Of Review: This study aims to present the current landscape of immunotherapy in the management of small bowel neuroendocrine tumors and identify ongoing and future targets for improved response....
5.
Meng Q, Halfdanarson T, Bornhorst J, Jann H, Shaheen S, Shi R, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5559-5567.
PMID: 39453770
Purpose: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are relatively indolent but can be more aggressive. The current recommendations for using serum chromogranin A (CgA) for patients with GEP-NET are equivocal. This study...
6.
Song Y, Chen E, Chiang Y, Yao J, Halperin D, Chatterjee D, et al.
J Surg Oncol
. 2024 Sep;
PMID: 39257200
Background And Objectives: Not all gastric neuroendocrine tumors (GNETs) may be classified into one of the three described clinicopathologic subtypes. The purpose of this study was to better characterize GNET...
7.
Hornstein N, Zeineddine M, Gunes B, Pellatt A, Knafl M, Zhu H, et al.
Cancer Res Commun
. 2024 May;
4(5):1363-1368.
PMID: 38709066
Purpose: Appendiceal adenocarcinoma (AA) remains an orphan disease with limited treatment options for patients unable to undergo surgical resection. Evidence supporting the efficacy of combined VEGF and PD-1 inhibition in...
8.
AghaAmiri S, Ghosh S, Vargas S, Halperin D, Azhdarinia A
J Med Chem
. 2024 Feb;
67(4):2425-2437.
PMID: 38346097
Temozolomide (TMZ) is a DNA alkylating agent that produces objective responses in patients with neuroendocrine tumors (NETs) when the DNA repair enzyme O-methylguanine-DNA methyltransferase (MGMT) is inactivated. At high doses,...
9.
Cordero-Hernandez I, Ross A, Dasari A, Halperin D, Chasen B, Yao J
Endocr Relat Cancer
. 2024 Feb;
31(4).
PMID: 38329269
We observed that some patients with well-differentiated neuroendocrine tumors (NET) who received peptide receptor radionuclide therapy (PRRT) with Lutetium-177 (177Lu) DOTATATE developed rapid disease progression with biopsy-proven histologic transformation to...
10.
Fahrmann J, Wasylishen A, Pieterman C, Irajizad E, Vykoukal J, Wu R, et al.
J Clin Endocrinol Metab
. 2023 Jun;
108(12):3260-3271.
PMID: 37307230
Purpose: Patients with multiple endocrine neoplasia type 1 (MEN1) are predisposed to develop duodenopancreatic neuroendocrine tumors (dpNETs), and metastatic dpNET is the primary cause of disease-related mortality. Presently, there is...